Jim Cramer in a latest program mentioned an analyst downgrade on The J. M. Smucker Company (NYSE:SJM) and reiterated that he ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...

Gemma Collins hopes that dropping two dress sizes thanks to weight loss jabs will free her from the pressure of trying to ...

"As a singer, few things scare me more than acid reflux," he admitted. That said, Jelly Roll doesn’t judge those who do use ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal. But weight loss doesn't discriminate ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.